Innovent Biologics partners with Takeda for new therapies; global collaboration effective after satisfying conditions.

Innovent Biologics, a company listed on the Hong Kong Stock Exchange under the ticker symbol 01801, recently revealed that their partnership with Takeda, a multinational pharmaceutical company listed on both the Tokyo Stock Exchange under the symbol 4502 and the New York Stock Exchange under the symbol TAK, has been finalized. The collaboration has officially commenced after meeting all the necessary requirements for closure.